REMARKS

The present Application has been amended such that reference to the figures corresponds to the designations in the formal drawings (e.g. specification now refers to figure "8A" rather than "8.1"). The Application has also been amended to remove reference to Figures 9A-B, 10, and 11A-D, which were inadvertently omitted when the present Continuation Application was filed. It is noted that these Figures are not necessary as the present claims find full support in the remainder of the Specification.

In regard to Figures 9A-B and 10, the results presented in these figures are also described in the text of Example 8. As such, the omission of Figures 9A-B and 10 does not affect the results described in Example 8. In regard to Figures 11A-D, the results presented in Figures 11A-D are also described in the text of Example 9. Moreover, the results presented in Figures 11A-D relate to testing anti-IL-6, anti-IL-8, and Anti-IL-12 (not anti-TNFα), and therefore are not related to the pending claims.

It is also noted that Figure 12 has been renumbered as Figure 9 such that the figure numbers go in order.

If the Examiner wishes to discuss this case, Applicants encourage the Examiner to call the undersigned at 608-218-6900 at the Examiner's convenience.

Dated: August 2, 2004

ason R. Bond

Registration No. 45,439

MEDLEN & CARROLL, LLP 101 Howard Street, Suite 350 San Francisco, California 94105 608/218-6900